Oncotarget

Research Papers:

A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis

Guideock Kwon, Md Jamal Uddin, Gayoung Lee, Songling Jiang, Ahreum Cho, Jung Hwa Lee, Sae Rom Lee, Yun Soo Bae, Sung Hwan Moon, Soo Jin Lee, Dae Ryong Cha and Hunjoo Ha _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:74217-74232. https://doi.org/10.18632/oncotarget.18540

Metrics: PDF 1217 views  |   HTML 2336 views  |   ?  


Abstract

Guideock Kwon1,*, Md Jamal Uddin1,*, Gayoung Lee1, Songling Jiang1, Ahreum Cho1, Jung Hwa Lee1, Sae Rom Lee2, Yun Soo Bae2, Sung Hwan Moon3, Soo Jin Lee3, Dae Ryong Cha4 and Hunjoo Ha1

1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, Korea

2Department of Life Science, Ewha Womans University, Seoul, Korea

3Aptabio Therapeutics Inc, Yongin-si, Korea

4Department of Internal Medicine, Division of Nephrology, Korea University, Seoul, Korea

*These authors contributed equally to this work

Correspondence to:

Hunjoo Ha, email: hha@ewha.ac.kr

Keywords: APX-115, diabetic kidney disease, mitochondria and peroxisome, oxidative stress, pan-Nox inhibitor

Received: March 24, 2017     Accepted: June 05, 2017     Published: June 16, 2017

ABSTRACT

NADPH oxidase (Nox)-derived reactive oxygen species (ROS) are increasingly recognized as a key factor in inflammation and extracellular matrix accumulation in diabetic kidney disease. APX-115 (3-phenyl-1-(pyridin-2-yl)-4-propyl-1-5-hydroxypyrazol HCl) is a novel orally active pan-Nox inhibitor. The objective of this study was to compare the protective effect of APX-115 with a renin-angiotensin system inhibitor (losartan), the standard treatment against kidney injury in diabetic patients, on streptozotocin (STZ)-induced diabetic kidney injury. Diabetes was induced by intraperitoneal injection of STZ at 50 mg/kg/day for 5 days in C57BL/6J mice. APX-115 (60 mg/kg/day) or losartan (1.5 mg/kg/day) was administered orally to diabetic mice for 12 weeks. APX-115 effectively prevented kidney injury such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, and inflammation as well as oxidative stress in diabetic mice, similar to losartan. In addition, both APX-115 and losartan treatment effectively inhibited mitochondrial and peroxisomal dysfunction associated with lipid accumulation. Our data suggest that APX-115, a pan-Nox inhibitor, may become a novel therapeutic agent against diabetic kidney disease by maintaining peroxisomal and mitochondrial fitness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18540